Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2022 01:52 ET | Source: SynAgile Corporation

SynAgile Corporation Announces Positive Phase 2 Top Line Results for DopaFuse® Levodopa-Carbidopa Delivery System

SAN JOSE, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com) today announced positive results from its Phase 2 clinical trial of continuous levodopa-carbidopa (LD-CD)...
September 01, 2022 00:52 ET | Source: SynAgile Corporation

SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System

SAN JOSE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com) is pleased to announce it has completed enrollment of its clinical trial evaluating the DopaFuse Delivery...
October 27, 2021 02:58 ET | Source: SynAgile Corporation

First Patient Treated with the DopaFuse® Delivery System

WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa)...
September 22, 2021 01:22 ET | Source: SynAgile Corporation

SynAgile Corporation Announces Closing of Financing, Appointment of Mr. Michael McNamara to the Board of Directors, and Appointment of Dr. C. Warren Olanow as Chief Medical Officer

WILSON, Wyoming, Sept. 22, 2021 (GLOBE NEWSWIRE) -- SynAgile Corporation (www.SynAgile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its...